199 related articles for article (PubMed ID: 20941459)
21. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban.
Houghton DE; Casanegra AI; Peterson LG; Cochuyt J; Hodge DO; Vlazny D; McBane RD; Froehling D; Wysokinski WE
Am J Hematol; 2020 Jul; 95(7):817-823. PubMed ID: 32267011
[TBL] [Abstract][Full Text] [Related]
22. Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes.
Beyer-Westendorf J; Gehrisch S; Stange T; Tittl L; Siegert G; Weiss N
Thromb Res; 2015 Aug; 136(2):261-6. PubMed ID: 26071672
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
24. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
[TBL] [Abstract][Full Text] [Related]
26. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
27. Apixaban: an oral direct factor-xa inhibitor.
Jiménez D; Yusen RD; Ramacciotti E
Adv Ther; 2012 Mar; 29(3):187-201. PubMed ID: 22354465
[TBL] [Abstract][Full Text] [Related]
28. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
[TBL] [Abstract][Full Text] [Related]
29. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
30. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
31. Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis.
Schumacher WA; Bostwick JS; Stewart AB; Steinbacher TE; Xin B; Wong PC
J Cardiovasc Pharmacol; 2010 Jun; 55(6):609-16. PubMed ID: 20224421
[TBL] [Abstract][Full Text] [Related]
32. Deep vein thrombosis and novel oral anticoagulants: a clinical review.
Burgazli KM; Atmaca N; Mericliler M; Parahuleva M; Erdogan A; Daebritz SH
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(23):3123-31. PubMed ID: 24338453
[TBL] [Abstract][Full Text] [Related]
33. New antithrombotic drugs: potential for use in oncology.
Levine MN
J Clin Oncol; 2009 Oct; 27(29):4912-8. PubMed ID: 19738103
[TBL] [Abstract][Full Text] [Related]
34. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
Breddin HK; Kadziola Z; Scully M; Nakov R; Misselwitz F; Kakkar VV
Thromb Haemost; 2003 Feb; 89(2):272-7. PubMed ID: 12574806
[TBL] [Abstract][Full Text] [Related]
35. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
Christersson C; Oldgren J; Bylock A; Siegbahn A; Wallentin L
Eur Heart J; 2007 Mar; 28(6):692-8. PubMed ID: 17314111
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Apixaban and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis after Total Knee Arthroplasty in Older Adults.
Jiang H; Meng J; Guo T; Zhao JN; Wang YC; Wang J; Qiu Y; Ding H
Yonsei Med J; 2019 Jul; 60(7):626-632. PubMed ID: 31250576
[TBL] [Abstract][Full Text] [Related]
37. Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside.
Poredos P; Jezovnik MK
Curr Drug Targets; 2018; 19(6):577-580. PubMed ID: 25981607
[TBL] [Abstract][Full Text] [Related]
38. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
39. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Martin MT; Nutescu EA
Curr Med Res Opin; 2011 Nov; 27(11):2123-31. PubMed ID: 21942466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
